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Glioblastoma (GBM) is the most common malignant brain tumour among adult patients and
represents an almost universally fatal disease. Novel therapies for GBM are being devel-
oped under the orphan drug legislation and the knowledge on the molecular makeup of this
disease has been increasing rapidly. However, the clinical outcomes in GBM patients with
currently available therapies are still dismal. An insight into the current drug development
pipeline for GBM is therefore of particular interest.
Objectives
To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug desig-
nations for compounds intended to treat GBM.
Methods
Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan
Drug Product database between 1983 and 2020. STROBE criteria were respected.
Results
Four orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treat-
ment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations
were subsequently withdrawn for unknown reasons. The number of orphan drug designa-
tions per year shows a growing trend. In the last decade, the therapeutic mechanism of
action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs
(median year of designation 2008) to immunotherapeutic approaches and small molecules
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(median year of designation 2014 and 2015 respectively) suggesting an increased focus on
precision in the therapeutic mechanism of action for compounds the development pipeline.
Conclusion
Despite the fact that current pharmacological treatment options in GBM are sparse, the drug
development pipeline is steadily growing. In particular, the surge of designated immunother-
apies detected in the last years raises the hope that elaborate combination possibilities
between classical therapeutic backbones (radiotherapy and chemotherapy) and novel, cur-
rently experimental therapeutics may help to provide better therapies for this deadly disease
in the future.
Introduction
High grade gliomas account for the majority of brain tumour related deaths in children and
adults. Considering all age groups together, glioblastoma represents the most common malig-
nant brain tumour (43,5% of all malignant brain tumours [1]).
Albeit being rare in absolute numbers, glioblastomas represent a universally fatal disease
class for approximately 15,000 patients per year in the United States [1]. While the last years
have seen a surge in publications that highlight intertumoural and intratumoural diversity [2,
3] in these tumours, our growing understanding of the pathophysiological processes that
underlie the disease could so far not yet be translated into therapeutic success.
To date, a wealth of studies has identified the typical genetic alterations that occur in glio-
blastoma: Mutations in IDH1 or, for paediatric glioblastomas, the two frequently occurring
histone H3.3 gene mutations (H3.3: pK27M and H3.3: pG34R/V) are just three examples of
common genetic mutations that define distinct molecular classes of glioblastoma. The well-
known mutations identified in glioblastoma have subsequently lead to the identification of epi-
genetic and transcriptomic mechanisms which perpetuate the disease: examples of this are the
hypermethylation of CpG islands in IDH1-mutant glioblastoma [4] and the loss of histone
H3.3 K27me3 in H3.3 mutant glioblastomas [5].
Despite the vast increase in knowledge about the genome, epigenome and transcriptome of
glioblastoma, clinical outcomes have not changed and drug development in glioblastoma is
lagging behind the significant advances in glioblastoma (epi)genomics. While some of these
genetic targets can be used therapeutically, the majority of them are unsuitable as a drug tar-
gets although they may offer the prospect of use in immunotherapy.
Thus, there is an unequivocal medical need for novel compounds or combinations of com-
pounds that are able to put a hold on disease progression.
The U.S. Orphan Drug Act of 1983 was intended to incentivize drug development in rare
diseases including rare cancers by providing protocol assistance, orphan grants programs, tax
credit for 50% of clinical trial costs, U.S. Food and Drug Administration (FDA) fee waiver,
and 7 years of marketing exclusivity [6]. Between 1983 and 2015, more than a third of all
orphan drug approvals (N = 177 out of a total of 492, i.e., 36%) were related compounds
intended to treat rare cancers [7].
While there may be manifold reasons for a clinical failure of novel drugs, a comprehensive
view on the status of designated compounds for the indication glioblastoma is still lacking.
In particular, it remains unclear which substance classes and therapeutic principles for glio-
blastoma have entered the market or are under development. This knowledge is instructive as
PLOS ONE The drug development landscape in glioblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0252924 July 7, 2021 2 / 14
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: ALL, Acute lymphoblastic leukemia;
AML, Acute myeloid leukemia; CAR, Chimeric
antigen receptor; CLL, Chronic lymphocytic
leukemia; EGFR, Epidermal growth factor receptor;
FDA, Food and drug administration; GBM,
Glioblastoma; GIST, Gastrointestinal stroma
tumour; HCC, Hepatocellular carcinoma; HL,
Hemophagocytic lymphhistiocytosis; HSV, Herpes
simplex virus; MB, Medulloblastoma; MDS,
Myelodysplastic syndrome; MGMT,
Methylguaninmethyltransferase; MPN,
Myeloproliferative neoplasia; NC, Nasopharyngeal
carcinoma; NTRK, Neurotrophic tyrosine kinase;
SCD, Sickle cell disease; VEGF, Vascular
endothelial growth factor; VEGFR, Vascular
endothelial growth factor receptor.
the pharmacological principles which underlie the designated drugs may have changed over
time and thus may mirror the different directions of brain tumour research. We aim to analyse
the lessons that we have learned by assessing successes and failures in orphan drug develop-
ment in glioblastoma. Therefore, we present a cross-sectional, quantitative clinical-regulatory
insight into the status of FDA orphan drug designations for compounds intended to treat
GBM. This study covers the period between January 1983 and August 2020.
Methods
STROBE criteria (S1 Checklist) were respected for planning, conduct, analysis, and reporting
of this study [8]. We accessed the Orphan Drug Product designation database on 30 July 2020
at https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ and downloaded the information
on all designated drugs using the search term “Glioblastoma”. The list of drugs was then man-
ually cleared from non-oncological indications. An allocation to the field of "paediatric oncol-
ogy" or "adult oncology" was performed by a board-certified paediatric oncologist.
Disease entities which typically occur both in adult age and in the field of paediatric oncol-
ogy (such as lymphomas and osteosarcoma for instance) were allocated to both categories.
Others which almost typically occur in paediatric oncology such as ALL were considered only
for this area.
Subsequently, designated drugs that were intended to treat glioblastoma were characterized
according to their mode of action in the pharmacological classes “cytostatics”, “cellular/viral
immunotherapy”, “targeted therapies” or “others”. Targeted therapies were defined as sub-
stances for which at least one molecular target could be identified by literature research [9].
Compounds that could not be classified unequivocally were categorized as "others"–this class
also contained compounds that are being used as diagnostics.
In order to independently verify whether there were approved drugs for the treatment of
glioblastoma that were not listed in the U.S. Food and Drug Administration Orphan Drug
Product database, we conducted a full text search in the FDA drug label database (FDALabel,
https://nctr-crs.fda.gov/fdalabel/ui/search). Search terms were “glioblastoma” in the section
“indications and usage”. The database was accessed on 28 October 2020. Findings were juxta-
posed to the approved compounds identified from the search in Orphan Drug Product desig-
nation database as described above. In addition, we cross-validated whether or not the
compounds identified from the search in FDALabel were registered as orphan drugs.
Standard methods of descriptive statistics were applied. In particular, continuous variables
were summarized with mean, standard deviation, and median, minimum, and maximum val-
ues whereas categorical variables were summarized with frequencies and percentages. Ana-
lyzed groups included 1) approved and 2) designated compounds intended to treat
glioblastoma.
In order to determine the number of approved drugs, we first queried the downloaded data
from the Food and Drug Administration Orphan Drug Product database for FDA approved
drugs and curated the list by eliminating duplicate terms. Likewise, the data were analyzed for
designated compounds. In addition, we analyzed number and characteristics of orphan drug
designations for glioblastoma that were subsequently withdrawn. In order to put our findings
on orphan drug designations for glioblastoma into perspective within a global oncological con-
text we analysed orphan drug designations for all oncological indications currently listed in
the US Food and Drug Administration Orphan Drug Product database. For the review of com-
pounds which have been used in Glioblastoma trials, we accessed the clintrials.gov database
(URL: https://clinicaltrials.gov/) on 07th of April 2021 and downloaded all interventional trials
that were completed for the search term “glioblastoma” and for which data have been
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published. The compounds that were used in these trials were classified into the same catego-
ries that were applied for the designated compounds.
For statistical analysis and graphical display, we used the software R (version 3.5.0). For
plots, the program library ggplot2 was employed. We used the CONSORT checklist when writ-
ing our report [10]
Patient and public involvement: No patient involvement.
Results
Approved drugs for glioblastoma
A total of four compounds (Table 1) were approved by the FDA for the indication glioblas-
toma. Three of them were therapeutic compounds, one is 5-aminolevulinic acid which is a
photo-diagnostic substance for the intraoperative detection of resection margins [11].
These results were in line with the findings of the FDALabel database query: bevacizumab,
carmustine, and temozolomide list the indication "glioblastoma" on their FDA approved
labels. All of these drugs have been used in the clinical setting, however with discouraging
results and no improvement in the outcome of glioblastoma [12].
The small number of approved compounds prompted us to further explore the drug devel-
opmental landscape in this disease.
Designated drugs in glioblastoma
Given the low number of approved drugs that can be used in the clinical setting, we next
sought to get an overview on the drug development landscape in glioblastoma, trying to quan-
tify and qualify the drugs that are in the pipeline for this indication.
Overall, 162 compounds had an orphan drug designation for glioblastoma. Until 2016, the
number of drugs designated for the indication glioblastoma varied, but on average displayed
an increasing trend (Fig 1). For the last four years, this tendency seems to have reversed and
the number of designated compounds per year displays a downward trend. To be able to put
these findings in GBM into a global oncological drug development context, we assessed the
spectrum of all oncological—and paediatric oncological diseases with orphan drug
designations.
Our analysis here yielded 4618 compounds (out of a total of 5513 orphan drug designations
for any rare disease = 83%, Fig 2) that were designated for either a paediatric or an adult onco-
logical entity. As in glioblastoma, since 1984, the number of orphan drug designations for
adult oncology per year varied with an increasing trend and showed a peak of 342 compounds
in 2016. As expected, the number of compounds targeting typical disease entities from adult
oncology was consistently higher than in paediatric oncology (on average 37% higher). The
numeric pattern over time appeared to be similar in paediatric and adult orphan drug
designations.
Table 1. An overview on approved compounds for the indication “glioblastoma”.
Name Target structure Year of Approval Year of designation
5-aminolevulinic acid intraoperative optical imaging agent 2017 2013
Bevacizumab Inhibition of angiogenesis (antibody against VEGF) 2009 2006
Polifeprosan 20 with carmustine Implant to deliver the approved drug carmustine 2003 1989
Lomustine Alkylating compound 1976 unknown
Temozolomide Alkylating compound 2006 1998
https://doi.org/10.1371/journal.pone.0252924.t001
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To better understand the intended indications of these designated compounds, we then
analyzed, which tumour entities are targeted by these drugs.
Fig 3 shows the frequency distribution of FDA orphan drug designations for their respec-
tive oncological indications. Most oncological orphan drug designations for the adult patient
population were granted for lymphoma, pancreatic cancer, and glioblastoma. In contrast,
Fig 1. Barplot shows the number of new orphan drug designations for the indication glioblastoma per year (years without a new designation are not
shown).
https://doi.org/10.1371/journal.pone.0252924.g001
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lymphomas, glioblastoma and AML received the majority of orphan drug designations for
paediatric cancers.
(Fig 3A and 3B). Although some of these categories are quite heterogeneous and comprise
different entities (such as lymphomas which are in fact a group of genetically heterogeneous
diseases associated with divergent outcome), the predominance of these groups is remarkable
as they do not represent the oncological indications which occur most frequently but which
are associated with a high mortality. Thus, the designated compounds in fact address the
Fig 2. Barplot shows the number of orphan drug designations in paediatric oncology and in adult oncology per year.
https://doi.org/10.1371/journal.pone.0252924.g002
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unmet medical need of cancers which are associated with a high mortality despite not being
the most frequent ones [13].
Withdrawn orphan drug designations in glioblastoma (S1 Table)
Studying the compounds designated for glioblastoma which were subsequently withdrawn
from the market is instructive as it may highlight potential mechanistically interesting sub-
stances that never reached the clinic.
Fig 3. Barplot shows the distribution of entities in paediatric (A) and adult (B) oncological entities with orphan drug designations.
https://doi.org/10.1371/journal.pone.0252924.g003
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Our search in the FDA approved drugs database revealed 14 designated compounds which
were subsequently withdrawn from the drug development pipeline. Some of these drugs were
classical cytostatics, others displayed more innovative modes of action: cilengitide, for
instance, an integrin inhibitor [14] was among the withdrawn substances. Other, less well-
known substances included the glutamate receptor inhibitor talampanel and cintredekin besu-
dotox, an IL13 conjugated toxin, specifically targeting glioblastoma. Reasons for these with-
drawals were not published and are therefore, unfortunately, not known.
Pharmacological classes of designated drugs in glioblastoma
We next characterized the pharmacological classes which were designated per year. We there-
fore allocated the designated compounds into the broad categories "cytostatics", "targeted ther-
apy", "Cellular product/ Virus" and "others". The latter constitutes a heterogeneous group of
substances comprising intraoperative fluroescent dyes (as diagnostics), peptide vaccinations or
repurposed drugs such as cannabinoids which are approved for other indications and were
subsequently found to display anti-neoplastic properties (“repurposing”).
When regarding the designation per compound class over time, we found that the median
year of designation for cytostatic drugs was 2008 (Fig 4A). With an increasing knowledge on
both the genetic makeup of glioblastomas and the resulting therapeutic targets, the years
2010–2020 saw an increase in small molecule inhibitors, directed against specific molecular
structures (Fig 4A). An investigation on the nature of these therapeutic targets revealed a high
diversity: Compounds directed against VEGF or the VEGFR were most frequently found, but
there were also molecules directed against EGFR—a molecule prototypically mutated in sub-
sets of adult glioblastoma [2].
Similarly, immunotherapeutic approaches including dendritic cell vaccinations, or NK cell/
T-cell based therapies represents a focus of the last years compound designations. As cellular
and viral therapies represent a very diverse group, we dissected this category further (Fig 4B):
Remarkably, 45% (9/20) of all therapeutics proved to be virus based, the majority of which
being oncolytic viruses. In dendritic cell based therapies, the second largest group, the den-
dritic cells were mostly stimulated with autologous tumour lysates or with synthetic peptides
derived from glioblastomas, aiming to elicit an anti-tumour immune response in the host. The
glioma-based therapeutics mainly consist of autologous tumour cells, which were engineered
to express immunogenic peptides/antigenes (such as an aberrant IGF1-R receptor).
Although none of the latter therapeutics has been approved for glioblastoma so far, the
number of designated drugs in this category points to a high potential of these compounds in
the clinic.
To examine which designated drugs have been used in recently in the frame of completed
and ongoing clinical studies, we classified compounds that were contained in interventional
studies from the portal clintrials.gov (S2 Table). Among the completed drug trials, the majority
(102/141; 72,3%) included at least one compound designated or approved for the indication
“glioblastoma”. Notably many of these studies combined an approved compound (such as bev-
acizumab or temozolomide) with a more experimental drug. Among the completed studies,
only very few (5/141, 3,54%) made use of immunotherapeutic approaches either alone or in
combination with cytostatics, a number that may possibly rise in the future.
Discussion
Approved drugs in glioblastoma
The overall increase in orphan drug designations for the whole oncological field is also seen in
the case of glioblastoma (with an average of six designated drugs per year). In stark contrast to
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the number of designations, only six compounds were approved for this entity in the last 30
years—the most recent substance being bevacizumab, an antibody that targets VEGF, which
however did not show a survival benefit in large, placebo-controlled studies [15]. Thus, consid-
erable discussions are ongoing about whether the FDA-approval of bevacizumab should be
withdrawn again.
Fig 4. A) Dotplots show the substance classes of designated drugs in GBM, B) Pie chart shows the mode of action of designated immunotherapies/
cellular therapies for glioblastomas.
https://doi.org/10.1371/journal.pone.0252924.g004
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Other approved compounds for GBM include cytostatic drugs such as carmustine or temo-
zolomide. Temozolomide has become a frequently used standard therapy due to its generally
favourable toxicity profile. It is one of few drugs for which a biomarker has been identified:
The MGMT promoter governs expression of the corresponding gene. It represents the most
important resistance mechanism to an alkylating therapy and its hypermethylation has been
associated with a better outcome [16].
It is remarkable that so far no cellular or virus based immunotherapy has been granted
approval by the FDA, although there have been promising preclinical and clinical [17] studies
suggesting a potential benefit.
Of particular during the last years, the number of designated cellular therapies has
increased. Some of them employ T-cells with chimeric antigen receptors, others back on den-
dritic cell vaccinations.
Spectrum of indications for designated drugs
Overall, our study revealed a wealth of compounds designated for oncological indications
and an average increase in drug designations per year over time. However, this trend seemed
to continue only until the year 2016 which marked a turning point with a decrease in desig-
nated compounds per year from then on. Reasons for this decline in the last years may be
manifold. While the Corona-pandemic may have influenced the number of designated drugs
in 2020, the reasons for the receding numbers in the years 2017–2019 could be a lack of novel
anti-neoplastic agents that successfully undergo testing in clinical studies. Other reasons that
could negatively influence the process of compound designation are a lack of funding,
changes in the regulatory environment, or unsustainable businesses which may have grown
in these years.
While some of the substances that we highlight here were already discussed and contained
in a review by Lassen et al. [18], the surge in immunotherapeutic approaches which we high-
light here seems noteworthy. For many of these novel, immunotherapeutic products, no effi-
cacy data in the sense of randomized, placebo-controlled trials have been published. However,
safety of administration and first-in-human data are available for a number of medications:
The oncoloytic HSV-1 (G207) has demonstrated safety in a phase I study with a median sur-
vival of 7,5 months (after inoculation of the virus) [19] and good tolerability of the modified
virus. For another virus based immunotherapy (employing the genetically modified HSV
M032), a clinical protocol and non-human primate data on safety have been published, how-
ever Phase I data are not available to date [20].
Similar data exist for other immunotherapeutic products that use modified progenitor cells:
Hematopoietic progenitor cells, transfected with a mutant MGMT-receptor to enhance temo-
zolomide resistance of the hematopoietic system, were used within the frame of a phase I and
demonstrated a reasonable safety profile [21].
Overall, none of these medications has demonstrated ground-breaking progress in overall
survival in these preliminary data. However, promising Phase 1 data exists which is worthwhile
to be pursued further.
It is remarkable, that the majority of designated compounds in adult oncology targeted lym-
phomas, pancreatic cancer and glioblastoma. This does not necessarily reflect the epidemiolog-
ical spectrum of malignant diseases with breast cancer, lung cancer and prostate cancer being
the most frequent cancers. When, however, considering cancer mortality from these entities,
the designations certainly do meet a medical need.
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Withdrawn drugs in glioblastoma
Several orphan drug designations for glioblastoma were subsequently withdrawn without ever
having been approved. Unfortunately, the precise reason for these withdrawals is not known.
It would be interesting to capture this information transparently in public or even in the clini-
caltrials.gov database as this would allow the scientific community to learn from previous
experiences, and potentially avoid unnecessary exposure of subjects to clinical research. Possi-
ble reasons for failure may include a flawed scientific rationale, flawed trial design or unsus-
tainable business (https://termeerfoundation.org/collaborations accessed 06 October 2020
[22]).
Drug safety considerations and innovative aspects of drug development in
glioblastoma
Usually orphan drug development programs involve fewer patients and fewer clinical trials
than non-orphan drug development programs. No approved drug for glioblastoma was with-
drawn. This indicates that there were no major safety issues in the orphan drug development
process in this area that were detected in the post-approval pharmacovigilance process. With
respect to innovation in the process of granting approval to novel drugs, there is certainly
room to expedite this process: The only targeted drug among the approved compounds
remains bevacizumab. Until today, the impact of the US orphan drug act on the drug develop-
ment for glioblastoma has been limited: There are only four FDA orphan approvals for the
treatment of glioblastoma—one of them (5-aminolevulinic acid.) is a diagnostic compound.
There is, however, hope for progress. It is possible that more compounds may successfully
reach the clinic, because 60 orphan drug designations have been granted with an increasing
tendency in the last 5 years.
Barriers to a successful translation of preclinical findings to the clinic
GBM represents a genetically highly complex disease: When progressing, these tumours
undergo a complex, molecular evolution that results in an increase of genetic aberrations.
Thus, therapies which target only one specific molecular lesion fall short in controlling the
diverse number of other pathways which may contribute to tumour growth. However even
combination therapies (including small molecule inhibitors and classical cytotoxic com-
pounds) did not show the desired effects in clinical studies).
Further problems which are encountered in the management of glioblastoma include its
invasive nature and the impossibility to achieve a gross total resection owing to the infiltrative
growth, its high proliferation rate and the associated speed by which resistance mechanisms
toward applied therapies emerge. Despite a growing number of designated compounds and
molecular directed therapeutics only few of them address the molecular characteristics of the
genetic and epigenetic glioblastoma subgroups. As an example, the molecular mechanism that
drives H3K27M mutant glioblastomas is well described by now: A sequestration of the enzyme
PRC2 [5] leads to a global loss of the repressive histone mark H3K27me3. An inhibitor of
enzymes (GSK-J4) that catalyze the demethylation of H3K27me3, thus restoring this mark, has
been tested [23] but so far has not reached the status as a designated drug.
There is hope that immunotherapy- either antibody based on the inhibition of PD(L)1 or
by using cellular products such as CAR-T cells [24] or dendritic cells—may ultimately improve
the outcome for patients with glioblastoma. At the least, these agents represent combination
partners that may expand the portfolio of classically used cytotoxic drugs.
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Limitations
This analysis of orphan drug development in the field of oncology is limited to the data pro-
vided in U.S. Food and Drug Administration Orphan Drug Product database. Other geo-
graphic regions were not included in this study because the FDA database is considered
comprehensive. As orphan drug development is generally a global endeavour, we consider the
results of this analysis to be generalizable within the context of these limitations.
In summary, we conclude despite the fact that current pharmacological treatment options
in GBM are sparse, the drug development pipeline in GBM has been growing steadily until
2016 and the number of designated drugs is still at a high level since then [25]. In particular,
the surge of designated immunotherapies during the last years raises the hope that elaborate
combination therapies between classical therapeutic backbones (i.e. radiotherapy and chemo-
therapy) and these novel, currently experimental interventions may help to provide better
treatment options for this deadly disease in the future.
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